Home › Sclerosi multipla › New York › New York City
Studi clinici su Sclerosi multipla a New York City, NY
17 studi su Sclerosi multipla cercano partecipanti presso sedi a New York City e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study of the MIND Diet for Persons With Multiple Sclerosis
In reclutamento
- Mount Sinai Hospital, New York
Vancomycin Study in Multiple Sclerosis (MS)
In reclutamentoFase 1
- Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai, New York
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
In reclutamentoFase 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
In reclutamentoStudio osservazionale
- TG Therapeutics Investigational Trial Site, New York
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
In reclutamentoFase 1/2
- Mt. Sinai, New York
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
In reclutamentoFase 2
- NYU Langone Health, New York
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
In reclutamentoFase 1
- TG Therapeutics Investigational Trial Site, New York
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
In reclutamentoFase 1
- Research Site, New York
- Research Site, New York
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
In reclutamentoFase 1
- Columbia University Irving Medical Center, New York
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
In reclutamentoFase 2
- Mount Sinai School of Medicine, New York
Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS)
In reclutamentoFase 2
- NYU Langone Health, New York
Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Mount Sinai Hospital, New York
Genes and Environment in Multiple Sclerosis
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Columbia University Irving Center, New York
A Palliative Care Model Impact on Knowledge and Attitudes
In reclutamento
- Judith Jaffe Multiple Sclerosis Center, New York
- Hunter College, New York
NYSCF Scientific Discovery Biobank
In reclutamentoStudio osservazionale
- New York Stem Cell Foundation Research Institute, New York
Eccentric Exercise and Fatigue in Multiple Sclerosis
In reclutamentoStudio osservazionale
- Hunter College, Physical Therapy Department, City University of New York, New York
Effect of Cooling on Balance Performance in Multiple Sclerosis
In reclutamentoStudio osservazionale
- Hunter College, Physical Therapy Department, City University of New York, New York
Studi su Sclerosi multipla in altre città
- Chicago, IL15 studi
- Boston, MA14 studi
- Washington, DC13 studi
- Cleveland, OH9 studi
- St. Louis, MO8 studi
- Kansas City, KS8 studi
- Birmingham, AL8 studi
- San Francisco, CA8 studi
- Columbus, OH7 studi
- Aurora, CO7 studi
- Baltimore, MD7 studi
- Farmington Hills, MI6 studi
Altri studi a New York City
- Cancro al seno134 studi
- Cancro del polmone non a piccole cellule120 studi
- Cancro (tutti i tipi)110 studi
- Cancro alla prostata103 studi
- Cancro metastatico93 studi
- Cancro colorettale77 studi
- Cancro ovarico69 studi
- Cancro ai polmoni60 studi
- Cancro pancreatico60 studi
- Mieloma multiplo60 studi
- Cancro dell'endometrio52 studi
- Insufficienza cardiaca51 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.